2009
DOI: 10.1016/j.bbrc.2009.04.136
|View full text |Cite
|
Sign up to set email alerts
|

The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
123
0

Year Published

2011
2011
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 146 publications
(124 citation statements)
references
References 16 publications
1
123
0
Order By: Relevance
“…Although they affect many pathways besides autophagy, several studies have shown that these treatments have positive effects on inflammation, tubular injury, glomerulosclerosis, and podocyte injury in rodent models of DN. [73][74][75][76][77][78][79][80] Interestingly, Wen et al show that the treatment of diabetic mice with resveratrol impairs intraglomerular capillary rarefaction, suggesting that resveratrol attenuates diabetic nephropathy by modulating lox/lox control, Atg5 lox/lox control diabetic, Cdh5.Cre-atg5 lox/lox control and Cdh5.Cre-atg5 lox/lox diabetic mice. Data represent means §SEM of 3 (nondiabetic) or 4 (diabetic) mice.…”
Section: Discussionmentioning
confidence: 99%
“…Although they affect many pathways besides autophagy, several studies have shown that these treatments have positive effects on inflammation, tubular injury, glomerulosclerosis, and podocyte injury in rodent models of DN. [73][74][75][76][77][78][79][80] Interestingly, Wen et al show that the treatment of diabetic mice with resveratrol impairs intraglomerular capillary rarefaction, suggesting that resveratrol attenuates diabetic nephropathy by modulating lox/lox control, Atg5 lox/lox control diabetic, Cdh5.Cre-atg5 lox/lox control and Cdh5.Cre-atg5 lox/lox diabetic mice. Data represent means §SEM of 3 (nondiabetic) or 4 (diabetic) mice.…”
Section: Discussionmentioning
confidence: 99%
“…Although many studies have shown that mTORC1 is involved in glomerular hypertrophy [9,32,33], there has been limited evidence supporting the involvement of this pathway in podocyte hypertrophy in DN. However, recent studies have shown that mTORC1 effectors are upregulated in the podocytes of diabetic glomeruli, and podocytespecific mTORC1 inhibition attenuates not only diabetesinduced podocyte hypertrophy but also glomerulosclerosis [10,34].…”
Section: Discussionmentioning
confidence: 99%
“…Diabetes-induced podocyte hypertrophy requires G 1 /S cell-cycle arrest mediated by cyclin-dependent kinase inhibitors (CKIs) [5,8]. In addition, the activation of mTOR complex 1 (mTORC1) and its downstream effectors, including eukaryotic elongation factor 4E-binding-protein-1 (4EBP1) and p70S6 kinase (p70S6K), play a pivotal role in diabetes-induced podocyte hypertrophy [9,10].…”
Section: Introductionmentioning
confidence: 99%
“…As it was previously demonstrated, in some tissues, i.e. mesangial cells or in renal cortex [11,12] the sensitivity of mTOR/p70-S6K pathway is preserved in insulin resistance and this pathway is being continuously over-stimulated due to the persisting hyperinsulinemia. Nevertheless, insulin signalling was significantly attenuated in white adipose tissue of HHTg rats ( Figure 3).…”
Section: Adipose Tissue Heparin-releasable Lpl Activity Is Higher In mentioning
confidence: 71%
“…Recent reports show that the effect of chronic hyperinsulinemia is tissue-specific. p70S6-kinase was highly activated in mesangial cells in diabetic obese db/db mice [11] and in the renal cortex of Zucker diabetic rats [12] and it is supposed to contribute to the renal hyperplasia. On the other hand, chronic hyperinsulinemia imposed on normal rats (5 days hyperinsulinemic-euglycemic clamp) had no effect on mTOR/p70-S6K pathway in white adipose tissue [9].…”
Section: Introductionmentioning
confidence: 99%